Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 09 02:35PM ET
318.20
Dollar change
-2.64
Percentage change
-0.82
%
IndexRUT P/E- EPS (ttm)-25.07 Insider Own15.74% Shs Outstand21.81M Perf Week-0.11%
Market Cap7.11B Forward P/E- EPS next Y-13.37 Insider Trans-0.79% Shs Float18.38M Perf Month-10.33%
Income-518.67M PEG- EPS next Q-4.48 Inst Own104.30% Short Float24.13% Perf Quarter35.01%
Sales76.81M P/S92.60 EPS this Y-20.24% Inst Trans-1.03% Short Ratio10.96 Perf Half Y24.84%
Book/sh35.64 P/B8.93 EPS next Y44.36% ROA-79.11% Short Interest4.43M Perf Year35.05%
Cash/sh44.90 P/C7.09 EPS next 5Y0.00% ROE-129.76% 52W Range168.25 - 368.29 Perf YTD37.52%
Dividend Est.- P/FCF- EPS past 5Y-55.24% ROI-57.92% 52W High-13.60% Beta-0.40
Dividend TTM- Quick Ratio5.93 Sales past 5Y0.00% Gross Margin95.23% 52W Low89.13% ATR (14)14.81
Dividend Ex-Date- Current Ratio5.98 EPS Y/Y TTM-30.31% Oper. Margin-713.49% RSI (14)54.60 Volatility3.53% 5.20%
Employees376 Debt/Eq0.15 Sales Y/Y TTM- Profit Margin-675.24% Recom1.53 Target Price373.00
Option/ShortYes / Yes LT Debt/Eq0.15 EPS Q/Q7.96% Payout- Rel Volume0.53 Prev Close320.84
Sales Surprise79.76% EPS Surprise27.09% Sales Q/Q- EarningsOct 31 BMO Avg Volume404.47K Price318.20
SMA20-1.31% SMA5016.95% SMA20025.08% Trades Volume169,895 Change-0.82%
Date Action Analyst Rating Change Price Target Change
Jun-28-24Initiated Cantor Fitzgerald Neutral
Jun-11-24Initiated Wolfe Research Outperform $382
Apr-22-24Initiated BofA Securities Underperform $150
Mar-15-24Upgrade B. Riley Securities Sell → Neutral $155 → $270
Mar-06-24Initiated Citigroup Buy $382
Feb-26-24Downgrade B. Riley Securities Neutral → Sell $155
Dec-20-22Reiterated Oppenheimer Outperform $170 → $250
Dec-19-22Upgrade Raymond James Underperform → Mkt Perform
Dec-19-22Reiterated Piper Sandler Overweight $203 → $280
Dec-19-22Reiterated H.C. Wainwright Buy $170 → $225
Dec-06-24 06:46AM
Nov-23-24 07:46AM
Nov-22-24 09:55AM
Nov-21-24 05:12PM
Nov-18-24 02:53AM
09:12PM Loading…
Nov-14-24 09:12PM
Nov-10-24 09:30AM
Nov-06-24 08:00AM
Nov-04-24 09:55AM
Nov-02-24 12:00PM
Nov-01-24 04:17PM
04:08PM
03:03AM
Oct-31-24 07:28AM
07:00AM
08:00AM Loading…
Oct-30-24 08:00AM
Oct-22-24 06:53AM
Oct-21-24 08:00AM
Oct-18-24 08:00AM
Oct-16-24 08:44AM
Oct-02-24 08:00AM
Oct-01-24 08:00AM
Sep-30-24 08:00AM
Sep-25-24 12:03AM
Aug-26-24 08:00AM
Aug-17-24 10:15AM
Aug-14-24 11:55PM
06:00AM
Aug-13-24 11:33AM
Aug-08-24 03:47AM
04:14PM Loading…
Aug-07-24 04:14PM
11:12AM
07:20AM
07:00AM
06:30AM
Aug-05-24 06:30AM
Aug-02-24 07:00AM
Jul-24-24 08:00AM
Jul-23-24 02:57PM
Jun-30-24 12:02PM
Jun-28-24 06:45AM
Jun-16-24 12:05PM
Jun-15-24 09:45AM
Jun-12-24 03:56PM
Jun-10-24 09:45AM
Jun-06-24 08:00AM
Jun-05-24 04:10PM
03:17PM
10:56AM
08:00AM
May-29-24 08:00AM
May-24-24 03:17AM
May-21-24 09:45AM
May-17-24 03:08AM
May-15-24 09:19PM
May-10-24 08:51AM
May-09-24 10:53AM
May-08-24 01:23PM
03:02AM
May-07-24 09:18AM
08:34AM
08:08AM
07:17AM
07:00AM
Apr-24-24 04:00PM
Apr-23-24 08:00AM
Apr-22-24 06:00AM
Apr-16-24 04:05PM
Apr-15-24 04:28PM
Apr-09-24 08:00AM
Apr-05-24 07:15AM
Apr-04-24 01:55AM
01:54AM
01:54AM
Apr-03-24 04:05PM
08:45AM
Apr-01-24 09:09PM
09:59AM
Mar-29-24 09:00AM
04:43AM
Mar-26-24 09:53AM
Mar-22-24 06:15AM
Mar-19-24 05:50AM
Mar-18-24 11:58PM
08:01PM
04:47PM
04:12PM
04:04PM
03:15PM
07:00AM
Mar-17-24 08:50AM
05:50AM
Mar-15-24 04:35PM
04:14PM
03:50PM
02:34PM
01:45PM
12:56PM
12:09PM
10:17AM
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CRAVES FRED BDirectorDec 03 '24Sale315.313,6001,135,12211,000Dec 05 04:46 PM
CRAVES FRED BDirectorNov 25 '24Sale350.303,4001,191,02814,600Nov 27 04:16 PM
CRAVES FRED BDirectorNov 25 '24Proposed Sale322.7310,0003,227,300Nov 25 04:10 PM
Huntsman CaroleChief Commercial OfficerNov 21 '24Sale316.92688218,04110,785Nov 22 04:30 PM
Carole HuntsmanOfficerNov 21 '24Proposed Sale316.92688218,040Nov 21 04:30 PM
Levy Richard SDirectorNov 07 '24Option Exercise7.365,00036,80016,012Nov 08 05:07 PM
Levy Richard SDirectorNov 07 '24Sale350.005,0001,750,00011,012Nov 08 05:07 PM
RICHARD S LEVYDirectorNov 07 '24Proposed Sale338.225,0001,691,100Nov 07 04:36 PM
Levy Richard SDirectorNov 01 '24Option Exercise7.365,00036,80016,012Nov 05 07:01 PM
Levy Richard SDirectorNov 01 '24Sale300.945,0001,504,70311,012Nov 05 07:01 PM
RICHARD S LEVYDirectorNov 01 '24Proposed Sale259.345,0001,296,700Nov 01 04:47 PM
Sibold William JohnPresident and CEOSep 09 '24Sale243.836,3631,551,49055,887Sep 11 09:51 PM
William John SiboldOfficerSep 09 '24Proposed Sale243.836,3631,551,514Sep 10 09:29 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Jun 14 '24Option Exercise87.091,900165,4717,400Jun 18 09:39 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Jun 14 '24Sale280.001,900532,0005,500Jun 18 09:39 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Jun 12 '24Option Exercise87.922,000175,8407,500Jun 14 09:44 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Jun 12 '24Sale285.002,000570,0005,500Jun 14 09:44 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.May 21 '24Sale231.341,036239,6685,500May 23 09:36 PM
CRAVES FRED BDirectorMay 14 '24Option Exercise103.0222,4892,316,844435,851May 16 09:53 PM
CRAVES FRED BDirectorMay 14 '24Sale212.8822,4894,787,404413,362May 16 09:53 PM
Taub RebeccaPres., R&D, and CMOApr 08 '24Option Exercise9.452,67625,288461,675Apr 10 08:53 PM
Taub RebeccaPres., R&D, and CMOApr 08 '24Sale245.992,676658,258458,999Apr 10 08:53 PM
FRIEDMAN PAUL ADirectorApr 08 '24Option Exercise9.4526,270248,251212,005Apr 10 08:50 PM
FRIEDMAN PAUL ADirectorApr 08 '24Sale246.1926,2706,467,491185,735Apr 10 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 03 '24Option Exercise9.4527,845263,135486,844Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 05 '24Option Exercise9.4527,506259,932486,505Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 04 '24Option Exercise9.4518,537175,175477,536Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 03 '24Sale245.1427,8456,825,976458,999Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 05 '24Sale243.3627,5066,693,790458,999Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 04 '24Sale242.9118,5374,502,823458,999Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 05 '24Option Exercise9.4527,613260,943213,348Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 03 '24Option Exercise9.4527,407258,996213,142Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 04 '24Option Exercise9.4518,710176,810204,445Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 05 '24Sale243.4027,6136,721,081185,735Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 03 '24Sale245.1227,4076,718,002185,735Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 04 '24Sale242.9618,7104,545,721185,735Apr 05 08:50 PM
Levy Richard SDirectorApr 01 '24Option Exercise63.9211,000703,16021,298Apr 03 08:47 PM
Levy Richard SDirectorApr 01 '24Sale257.4811,0002,832,33510,298Apr 03 08:47 PM
BATE KENNETHDirectorApr 01 '24Option Exercise57.9621,2771,233,18722,475Apr 03 08:44 PM
BATE KENNETHDirectorApr 02 '24Option Exercise105.0811,2121,178,15712,410Apr 03 08:44 PM
BATE KENNETHDirectorApr 01 '24Sale257.2621,2775,473,7791,198Apr 03 08:44 PM
BATE KENNETHDirectorApr 02 '24Sale244.4911,2122,741,2191,198Apr 03 08:44 PM
Daly James MDirectorApr 01 '24Option Exercise100.7921,5772,174,71122,775Apr 03 08:41 PM
Daly James MDirectorApr 02 '24Option Exercise105.0810,9121,146,63312,110Apr 03 08:41 PM
Daly James MDirectorApr 01 '24Sale257.2421,5775,550,5441,198Apr 03 08:41 PM
Daly James MDirectorApr 02 '24Sale244.5110,9122,668,0871,198Apr 03 08:41 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Sale238.502,000477,0005,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Sale232.502,000465,0005,667Dec 18 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 13 '23Buy219.3981,15917,805,6841,774,294Dec 14 06:10 PM
BAKER BROS. ADVISORS LPDirectorDec 14 '23Buy228.3220,6334,710,8931,793,403Dec 14 06:10 PM
BAKER BROS. ADVISORS LPDirectorDec 12 '23Buy218.3134,5787,548,6161,699,129Dec 14 06:09 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Option Exercise87.922,500219,8008,167Dec 14 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Option Exercise87.921,300114,2966,967Dec 14 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Sale225.402,500563,5005,667Dec 14 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Sale217.851,300283,2005,667Dec 14 04:30 PM